Low-dose apixaban comparable to full dose for preventing venous thromboembolism recurrence in patients with cancer

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of low-dose apixaban, experienced similar VTE recurrences and less bleeding as similar patients who received a full dose of the oral blood-thinning medication over the same extended period. These findings from the API-CAT trial were presented at the American College of Cardiology’s Annual Scientific Session (ACC.25).